PI3

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Tuesday, March 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

General Fusion and University of Lisbon Collaborate on State-of-the-Art Diagnostic for LM26 Plasma Injector

Retrieved on: 
Tuesday, December 12, 2023
DEMO, PI3, Research, Plasma, Physics, European, University, Temperature, Laser, General Fusion, Magnetized target fusion, ITER, Face, EUROfusion, IPFN, IST, Lithium

The custom diagnostic, being built in both Canada and Portugal, will unlock valuable new data about plasma density in General Fusion’s PI3 plasma injector before its plasmas are compressed in the company’s ground-breaking fusion demonstration, Lawson Machine 26 (LM26).

Key Points: 
  • The custom diagnostic, being built in both Canada and Portugal, will unlock valuable new data about plasma density in General Fusion’s PI3 plasma injector before its plasmas are compressed in the company’s ground-breaking fusion demonstration, Lawson Machine 26 (LM26).
  • The specialized device developed by General Fusion and IPFN’s world-leading experts in reflectometer diagnostics will measure plasma density on PI3 and LM26.
  • The IPFN team and General Fusion will complete the assembly and installation of the diagnostic on PI3 and start testing ahead of the assembly of LM26.
  • General Fusion is fast-tracking its technical progress to provide commercial fusion energy to the grid by the early to mid-2030s.

General Fusion Announces Funding to Build New Fusion Machine Targeting Scientific Breakeven by 2026

Retrieved on: 
Wednesday, August 9, 2023
UK Atomic Energy Authority Constabulary, The Honourable, Face, Electricity, CAD, BDC, Magnetized target fusion, Strategic Innovation Fund, MTF, Research, General Fusion, Temperature, Government of British Columbia, Government, PI3, Plasma, Climate change, Laser, Economic development, Partnership, Chevrolet Series F, GIC, Compression, Economics, Renewable energy, Lithium, Science, Innovation

To be built at the company's new Richmond headquarters, this ground-breaking machine is designed to achieve fusion conditions of over 100 million degrees Celsius by 2025, and progress toward scientific breakeven by 2026.

Key Points: 
  • To be built at the company's new Richmond headquarters, this ground-breaking machine is designed to achieve fusion conditions of over 100 million degrees Celsius by 2025, and progress toward scientific breakeven by 2026.
  • Called Lawson Machine 26 (LM26), the MTF demonstration is designed to be cost-efficient and produce results quickly using General Fusion’s unique approach to fusion.
  • Both are critical steppingstones to achieving LM26’s target of fusion conditions in 2025 and equivalent scientific breakeven in 2026.
  • Reference to breakeven in the context of LM26 refers to the deuterium-tritium breakeven equivalent using deuterium fuel, an industry-standard approach.

Nano Dimension Announces Sale to the University of Stuttgart Additively Manufactured Electronics (AME) DragonFly® IV System to be Used In Development of Quantum Sensors

Retrieved on: 
Monday, June 26, 2023
Pharmacy, University of Stuttgart, University, Electronics, 3D, AME, IIS, Research, IP, PI3, Government, Nature, 3D printing, Safety, Microscope, Physics

Nano Dimension’s most advanced 3D printer for electronics will go to the University’s Institute of Smart Sensors (IIS) and 3rd Institute of Physics (PI3).

Key Points: 
  • Nano Dimension’s most advanced 3D printer for electronics will go to the University’s Institute of Smart Sensors (IIS) and 3rd Institute of Physics (PI3).
  • The two groups are jointly working on the design and the integration of next-generation quantum devices as part of a government sponsored program known as Cluster4Future QSens (“QSens”).
  • This is particularly empowering when the work at-hand is the scalable integration of qubits for quantum sensing and computing.
  • This field is perfect use case for our AME system, DragonFly® IV, which can be used to make specialty electronic devices with the design freedom and shorter innovation cycles of additive manufacturing.”

Kura Oncology Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
KRAS, AACR, Postcholecystectomy syndrome, European Hematology Association, CRH, Cancer, Lung cancer, Kura, ID, FTI, PI3, Daunorubicin, Acute myeloid leukemia, Renal cell carcinoma, Congress, AML, Azacitidine, Dor, Investment, Patient, EGFR, KURA, EHA, CR, FLT3, Webcast, Research, Axitinib, FDA, Safety, IND, Disease, Video game, Pharmaceutical industry, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2023 were $25.2 million, compared to $20.9 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $11.4 million, compared to $11.9 million for the first quarter of 2022.
  • ET / 1:30 p.m. PT today, May 10, 2023, to discuss the financial results for the first quarter 2023 and to provide a corporate update.

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, May 8, 2023
Amgen, Chronic lymphocytic leukemia, Marketing, Neoplasm, Nektar Therapeutics, GAAP, Chemistry, Investment, Patient, Attention deficit hyperactivity disorder predominantly inattentive, Prostate cancer, Multiple myeloma, Pharmacokinetics, Mutation, Drug discovery, Growth, Hospital, Massachusetts General Hospital, D, Exercise, Pancreatic cancer, AACR, Conference call, Roche, Disclosure, Rama, Lung cancer, American Association for Cancer Research, NSCLC, Immunotherapy, PI3, Colorectal cancer, Cancer, Sanofi, Research, Therapy, MD Anderson Cancer Center, CRC, Phosphorylation, IO, CMC, Medication, Bristol Myers Squibb, SHP2, Harvard Medical School, Annual general meeting, Pharmaceutical industry, Medical imaging, Video game, Cryptocurrency, Genentech, Conference

REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2023, and provided an update on corporate progress.

Key Points: 
  • Conference call and webcast today at 4:30 p.m. Eastern Time
    REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2023, and provided an update on corporate progress.
  • The study is fully enrolled, and Revolution Medicines is on track to provide topline data from this study in the second half of 2023.
  • Net Loss: Net loss was $68.1 million for the quarter ended March 31, 2023, compared to net loss of $57.6 million for the quarter ended March 31, 2022.
  • Revolution Medicines will host a webcast this afternoon, May 8, 2023, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Safety, Bristol Myers Squibb, ID, FTI, FLT3, Cancer, QT interval, III, Farnesol, EGFR, IDH, Disease, EORTC, Organization, Research, IND, Webcast, FDA, Investment, Patient, Element, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASH, KRAS, PI3, CRH, Azacitidine, Renal cell carcinoma, Kura, KURA, Society, AML, HNSCC, Head, CR, PIK3CA, Daunorubicin, Data, Food, G&A, Lung cancer, Acute myeloid leukemia, Pharmaceutical industry, Video game

ET –

Key Points: 
  • ET –
    SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a corporate update.
  • Research and development expenses for the fourth quarter of 2022 were $22.7 million, compared to $21.0 million for the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $12.5 million, compared to $12.1 million for the fourth quarter of 2021.
  • ET / 1:30 p.m. PT today, February 23, 2023, to discuss the financial results for the fourth quarter and full year 2022 and to provide a corporate update.

Exascend Unveils 15.36 TB Ultra High-Capacity High-Availability Enterprise and Wide-Temperature U.2 SSDs

Retrieved on: 
Tuesday, February 14, 2023
PCI Express, RAID1, PLP, HDD, SSD, PI3, M.2, GB, Temperature, IOPS, Solid-state drive, TB, U.2, Computer data storage

This time around, Exascend is pushing the envelope of SSD storage density with its 15.36 TB U.2 offering.

Key Points: 
  • This time around, Exascend is pushing the envelope of SSD storage density with its 15.36 TB U.2 offering.
  • Exascend's 15.36 TB U.2 SSDs feature high I/O performance and low latency for optimized data processing time.
  • PE3 15.36 TB U.2 is available immediately, with the PI3 15.36 TB U.2 following suit in March.
  • To place an order, submit an inquiry to Exascend or reach out to your assigned Exascend representative.

Exascend Unveils 15.36 TB Ultra High-Capacity High-Availability Enterprise and Wide-Temperature U.2 SSDs

Retrieved on: 
Tuesday, February 14, 2023
PCI Express, RAID1, PLP, HDD, SSD, PI3, M.2, GB, Temperature, IOPS, Solid-state drive, TB, U.2, Computer data storage

This time around, Exascend is pushing the envelope of SSD storage density with its 15.36 TB U.2 offering.

Key Points: 
  • This time around, Exascend is pushing the envelope of SSD storage density with its 15.36 TB U.2 offering.
  • Exascend's 15.36 TB U.2 SSDs feature high I/O performance and low latency for optimized data processing time.
  • PE3 15.36 TB U.2 is available immediately, with the PI3 15.36 TB U.2 following suit in March.
  • To place an order, submit an inquiry to Exascend or reach out to your assigned Exascend representative.